March 30, 2011 at 11:20 PM SING VIA Pharmaceuticals Presents at Drug Discovery World Asia 2011, Singapore: Uncovering Opportunities for New Drugs to Treat Cardiometabolic Diseases Marina Bay Sands Hotel, Singapore
interesting 15-12g play, imo. The company just reinstated with the NV SOS on Thursday. The A/S per the SOS is only 50MM, and the O/S looks to be less than 30MM.
Quote: -------------------------------------------------------------------------------- Financial Information
No Par Share Count: 0 Capital Amount: $ 50,000.00 Par Share Count: 50,000,000.00 Par Share Value: $ 0.001
BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. Its lead products in development include BST-CarGel, a biodegradable gel for cartilage repair; BST-InPod for heel pain relief; BST-DermOn for chronic wound healing; BST-Ossifil for bone filling; BST-Ossifix for bone structural support; and BST-Disc for intervertebral disc restoration. The company’s products also comprise BST-Gel-based injectable products that deliver biotherapeutics to their targeted site of action; Arthro-BST, an arthroscopic device used for the non-destructive evaluation of cartilage degradation and/or repair; and Mach-1, a micromechanical testing system for evaluating the mecha...
Mr. Kugelman, age 44 is a principal in Atlanta Capital Partners for the past 10 years, providing corporate consulting in mergers, acquisitions, public relations to several publicly-traded clients. Mr. Kugelman has been in the Investment industry since 1986 and has held the National Association of Securities Dealers Series 7, 24, 63, and 66 licenses, as well as the Certified Financial Manager designation. In the past, he has worked for Thomson McKinnon, Bear Stearns, and Merrill Lynch. Mr. Kugelman graduated form Ball State University in 1986 with a Bachelor of Science degree in Business Administration.